MTN-002

The first study of a candidate topical microbicide in pregnant women that aimed to understand if and to what extent pregnancy affects how the body absorbs the active drug in the antiretroviral-based candidate microbicide tenofovir gel, and whether the drug can be transferred to the fetus.

See

Researchers report results of first microbicide trial in pregnant women [1]

Study indicates small amount of drug passes to fetus [1]

May 23, 2010

Trial is first to see if HIV prevention gels are safe for pregnant women & their babies [2]

Jun 12, 2008

MTN-002 Backgrounder [3]

MTN-002 Q&A [4]

See Also

MTN-002 Protocol [5]

MTN-016 [6]

Links:
[1] http://www.mtnstopshiv.org/node/1846
[2] http://www.mtnstopshiv.org/node/430
[3] http://www.mtnstopshiv.org/news/studies/mtn002/backgrounder
[4] http://www.mtnstopshiv.org/news/studies/mtn002/qa
[5] http://www.mtnstopshiv.org/sites/default/files/attachments/MTN%20002%20Final%20Version%201%200%20082907%20(2).pdf
[6] http://www.mtnstopshiv.org/news/studies/mtn016
[7] http://www.mtnstopshiv.org/print/820

Media Contacts:

Lisa Rossi -- Office: +1 412 641-8940 -- Mobile: +1 412 916-3315 -- Email: rossil@upmc.edu

Clare Collins -- Office: +1 412 641-7299 -- Mobile: +1 412 770-8643 -- Email: collcx@upmc.edu